| Date |
Title |
Rating |
| 2010-05-31 |
FAIR-HF study: Ferinject improves renal function in patients with CHF and iron deficiency |
None |
| 2010-05-31 |
Mucosis receives € 3M innovation credit line from Dutch Ministry for development of FluGEM influenza vaccine |
None |
| 2010-05-31 |
Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients |
None |
| 2010-05-31 |
Targeted Genetics's partner Celladon presents Phase II trial data with MYDICAR at Heart Failure Congress 2010 |
None |
| 2010-05-29 |
Sunitinib not effective in patients with papillary RCC: Researchers |
None |
| 2010-05-29 |
CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia |
None |
| 2010-05-28 |
Advaxis doses first patient in FDA-approved phase II CIN trial |
None |
| 2010-05-28 |
Relevare Pharmaceuticals to present CNSB015 Phase IIa results at international neuropathic pain congress |
None |
| 2010-05-28 |
VIVUS to present phase 3 data on avanafil for treatment of ED at AUA 2010 |
None |
| 2010-05-28 |
Advanced Life Sciences expands partnership with U.S. Government to assess Restanza against STI's |
None |
| 2010-05-28 |
Nymox Pharmaceutical announces symposium and panel discussion on NX-1207 drug for BPH |
None |
| 2010-05-28 |
CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial |
None |
| 2010-05-28 |
ARCA receives approval to begin enrollment of first therapeutic trial with GeoVax vaccine |
None |
| 2010-05-27 |
NOXXON Pharma closes €33 million Series D round of financing |
None |
| 2010-05-27 |
Toremifene reduces fracture risk in men with prostate cancer after initiation of androgen deprivation therapy |
None |
| 2010-05-27 |
YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC |
None |
| 2010-05-27 |
Pfizer plans recruitment halt to EMPHASIS-HF trial |
None |
| 2010-05-27 |
FDA, EMA approve Repligen's proposal for Phase 3 re-read in RG1068 trial for pancreatic imaging |
None |
| 2010-05-27 |
Shark cartilage extract shows no benefit for patients with advanced non-small cell lung cancer |
None |
| 2010-05-27 |
Patients with transformed lymphoma show positive response to lenalidomide: Research |
None |
| 2010-05-27 |
New study holds promise for patients with LCA |
None |
| 2010-05-27 |
Logical Therapeutics closes $16.9 million Series C equity financing round |
None |
| 2010-05-26 |
CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer |
None |
| 2010-05-26 |
Presidio Pharmaceuticals to advance PPI-1301 inhibitor from HCV NS5A program into clinical development |
None |
| 2010-05-26 |
Study demonstrates efficacy of CONCERTA in treating ADHD in presence of comorbid learning disability |
5 |
| 2010-05-26 |
Positive results from 3 year follow-up of BPH patients treated with NX-1207 in Study NX02-0016 |
None |
| 2010-05-26 |
Positive results reported from Phase IIa clinical trial of intranasal oxytocin for CDH |
None |
| 2010-05-26 |
Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept |
None |
| 2010-05-26 |
Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen |
5 |
| 2010-05-26 |
GTx reports top line results from toremifene Phase III clinical trial for prostate cancer |
None |
| 2010-05-25 |
Rockwell Medical's SFP Phase IIb data accepted for presentation at XLVII ERA-EDTA Congress |
None |
| 2010-05-25 |
CoDa Therapeutics reports positive results from Phase 2 study of NEXAGON for chronic venous leg ulcers |
5 |
| 2010-05-25 |
Cytochroma reports positive Phase 1/2 results for CTAP101 Capsules in non-dialysis CKD patients |
None |
| 2010-05-25 |
Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010 |
None |
| 2010-05-25 |
REDUCE trial data published in the online version of European Urology |
4 |
| 2010-05-25 |
DMC recommends ARIAD continue Phase 3 trial of oral ridaforolimus for metastatic sarcomas to final analysis |
None |
| 2010-05-25 |
ImmunoGen to present clinical data on IMGN388 solid tumor compound at 2010 ASCO |
None |
| 2010-05-25 |
NovaBay Pharmaceuticals completes enrollment in Phase 2a trial of NVC-422 for treatment of impetigo |
None |
| 2010-05-25 |
Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS |
None |
| 2010-05-25 |
Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting |
None |
| 2010-05-25 |
Neuralstem updates progress of ongoing Phase I human clinical trial for ALS |
5 |
| 2010-05-25 |
Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC |
None |
| 2010-05-24 |
Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA |
None |
| 2010-05-24 |
Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed |
None |
| 2010-05-24 |
Phase 1 clinical trial of OXY111A initiated |
None |
| 2010-05-24 |
Lytix Biopharma receives approval to initiate Phase I/IIa clinical trial of Lytixar for MRSA |
None |
| 2010-05-24 |
Bayer Healthcare Pharmaceuticals presents Phase 3 clinical data on gadobutrol |
None |
| 2010-05-21 |
Bristol-Myers Squibb announces positive results from Phase 2 study of ipilimumab in patients with NSCLC |
None |
| 2010-05-21 |
New data on ARIAD's AP24534 and ridaforolimus accepted for presentation at ASCO 2010 |
None |
| 2010-05-21 |
ImmunoCellular Therapeutics to present clinical results of ICT-107 dendritic cell immunotherapy at 46th ASCO |
None |
| 2010-05-21 |
Clinical data evaluating CAL-101 in patients with hematologic malignancies to be presented at ASCO 2010 |
None |
| 2010-05-21 |
Ligand Pharmaceuticals secures milestone and royalty interest in IL-9 antibody program |
None |
| 2010-05-21 |
ArQule announces presentations on ARQ 197 c-Met inhibitor at 2010 ASCO |
None |
| 2010-05-21 |
Data on retreatment experiences with brentuximab vedotin in clinical trials to be presented at 2010 ASCO |
None |
| 2010-05-21 |
PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting |
None |
| 2010-05-21 |
Combination of reovirus and carboplatin/paclitaxel shows promising anticancer activity in SCCHN |
None |
| 2010-05-21 |
Interim data from Phase 2 clinical trial of sapacitabine in patients with MDS to be presented at ASCO 2010 |
None |
| 2010-05-21 |
New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting |
None |
| 2010-05-21 |
Researchers identify drug that improves communication between nerve cells in Phelan-McDermid Syndrome |
4.5 |
| 2010-05-21 |
Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO |
None |
| 2010-05-21 |
Provectus to present further positive data from PV-10 Phase 2 clinical trial for metastatic melanoma at ASCO |
None |
| 2010-05-21 |
ZIOPHARM Oncology to present phase II data from PICASSO trial for soft tissue sarcoma at ASCO meeting |
None |
| 2010-05-21 |
Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting |
None |
| 2010-05-21 |
Phase III PRIMA study data of Rituxan to be featured at 46th ASCO |
None |
| 2010-05-21 |
Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation |
None |
| 2010-05-21 |
Genentech to present new data for targeted cancer medicines at 46th ASCO |
None |
| 2010-05-21 |
Infinity to present data from Hsp90 chaperone and Hedgehog pathway inhibitor programs at 2010 ASCO |
None |
| 2010-05-21 |
Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010 |
None |
| 2010-05-21 |
Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO |
None |
| 2010-05-21 |
ZymoGenetics' IL-21 Phase 2 trial data in metastatic melanoma to be presented at ASCO annual meeting |
None |
| 2010-05-21 |
Positive results from Phase 1 study evaluating IV administration of JX-594 to metastatic cancer patients |
None |
| 2010-05-21 |
Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010 |
None |
| 2010-05-21 |
Preliminary data of BIBW 2992 in head and neck cancer, NSCLC to be presented at ASCO 2010 |
None |
| 2010-05-21 |
Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO |
None |
| 2010-05-21 |
Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer |
None |
| 2010-05-20 |
Phase 1/2 clinical trial data of Oncophage for recurrent high-grade glioma |
None |
| 2010-05-20 |
Recruitment of children and adults with type 1 diabetes commences in Protege Encore teplizumab trial |
None |
| 2010-05-20 |
Update on Phase I clinical trials of Oncopore for treatment of cancer |
None |
| 2010-05-20 |
Inviragen initiates first clinical trial of DENVax vaccine to protect against dengue fever |
None |
| 2010-05-20 |
Phase I study of SNS-032 demonstrates safety, potential clinical activity in treating B-cell malignancies |
None |
| 2010-05-19 |
Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD |
None |
| 2010-05-19 |
Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010 |
None |
| 2010-05-19 |
Oncolytics Biotech initiates Phase I study of REOLYSIN and FOLFIRI in colorectal cancer patients |
None |
| 2010-05-19 |
Discovery Labs revalidates optimized BAT in program to gain FDA approval of Surfaxin for RDS |
None |
| 2010-05-19 |
Cell Therapeutics reports cardiac safety results from phase II trial of pixantrone in CHOP-R regimen |
None |
| 2010-05-19 |
Evotec announces compound in strategic alliance with Boehringer Ingelheim advances into clinical trials |
None |
| 2010-05-19 |
Pre-menopausal women with HSDD report clinically meaningful improvement with flibanserin |
2 |
| 2010-05-19 |
Pearl Therapeutics presents data supporting development of PT003 combination bronchodilator product |
None |
| 2010-05-19 |
New multi-center follow-up study of NX-1207 for treatment of BPH to be completed |
None |
| 2010-05-19 |
Generex Biotechnology's Phase I study data of AE37 for prostate cancer published |
None |
| 2010-05-19 |
Roche, Biogen Idec discontinue ocrelizumab clinical development programme for RA |
None |
| 2010-05-19 |
Flibanserin benefits pre-menopausal women with Hypoactive Sexual Desire Disorder |
4 |
| 2010-05-19 |
Aprea to present poster on phase I/II clinical trial of APR-246 anticancer compound at ASCO Meeting |
None |
| 2010-05-19 |
Oncolytics announces publication of Phase Ia/Ib U.K. clinical trial results of REOLYSIN for cancer |
None |
| 2010-05-18 |
Harbor BioSciences announces presentation of new data from Apoptone Phase I/IIa trial at ASCO Annual Meeting |
None |
| 2010-05-18 |
Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial |
None |
| 2010-05-18 |
KaloBios Pharmaceuticals' KB001 promising in prevention of serious lung infection |
None |
| 2010-05-18 |
Thai AIDS vaccine trial: Risk of HIV infection can be reduced with a vaccine |
None |
| 2010-05-18 |
Cerenis' CER-001 Phase 1 study data supports continued clinical development for acute coronary syndromes |
None |
| 2010-05-18 |
Phase II ALSTAR trial: Talampanel is safe for ALS patients |
5 |
| 2010-05-18 |
UMPIRE trial of Red Heart Pill launched to combat cardiovascular problems |
5 |
| 2010-05-18 |
FibroGen's FG-3019 human monoclonal antibody against CTGF reverses progression of lung fibrosis |
4.2 |
| 2010-05-17 |
BaroFold licenses PreEMT Technology to Nuron Biotech for development of BaroFeron |
None |
| 2010-05-17 |
Mpex Pharmaceuticals presents Phase 2b trial results of Aeroquin for cystic fibrosis at ATS Annual Meeting |
None |
| 2010-05-17 |
FDA grants NeoPharm's IL13-PE38QQR orphan-drug designation for treatment of IPF |
None |
| 2010-05-17 |
Argos Therapeutics presents AGS-004 autologous dendritic cell therapy Phase 2a trial data at 19th CAHR |
None |
| 2010-05-17 |
Hemispherx Biopharma to conduct study of Ampligen antiviral in China |
None |
| 2010-05-17 |
ARCA biopharma announces SPA agreement with FDA for bucindolol clinical trial |
None |
| 2010-05-17 |
Emergent BioSolutions' anthrax monoclonal antibody IND for Phase I study clears FDA review |
None |
| 2010-05-17 |
Celldex Therapeutics commences screening in CDX-1307 Phase 2 study for bladder cancer |
None |
| 2010-05-17 |
Tranzyme Pharma to present data on prokinetic agent TZP-101 in GI recovery at ASCRS 2010 |
None |
| 2010-05-17 |
Polypill to be tested in new heart disease trial |
None |
| 2010-05-17 |
Roche to commence clinical study of TB-403 in patients with colorectal and ovarian cancer |
None |
| 2010-05-17 |
Treatment with MP-376 reduces P. aeruginosa in CF patients: Research |
None |
| 2010-05-15 |
Inhibitex commences trials on INX-189 for treatment of Hepatitis C infections |
5 |
| 2010-05-15 |
Merck, Cardiome Pharma show superiority of BRINAVESS to amiodarone injection |
None |
| 2010-05-14 |
Data from RGN-259 study published in Archives of Ophthalmology |
None |
| 2010-05-14 |
Phase 2a study results of Aerosurf for prevention of RDS in premature infants published |
None |
| 2010-05-14 |
Inhibitex reports net loss of $4.8M for first-quarter 2010 |
None |
| 2010-05-14 |
International study to test effectiveness of celecoxib in preventing growth of precancerous polyps |
None |
| 2010-05-14 |
DMC recommends Celsion to continue enrollment in ThermoDox clinical study for primary liver cancer |
None |
| 2010-05-14 |
Jennerex to present key data on JX-594 Phase 1 dose escalation clinical study at ASGCT Annual Meeting |
None |
| 2010-05-14 |
Phase IIb trail results of epratuzumab in lupus patients to be presented at EULAR 2010 |
None |
| 2010-05-14 |
Transdel Pharmaceuticals reports lower net loss of $0.9 million for first-quarter 2010 |
None |
| 2010-05-14 |
RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug |
None |
| 2010-05-14 |
Derma Sciences first-quarter net sales up 23% to $12,844,382 |
None |
| 2010-05-14 |
Chimerix commences first-in-human study of CMX157 for HIV |
None |
| 2010-05-13 |
Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED |
None |
| 2010-05-13 |
ARYx Therapeutics decreases first-quarter net loss to $6.4 million |
None |
| 2010-05-13 |
Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia |
5 |
| 2010-05-13 |
Genta first-quarter net loss increases to $166.6 million |
None |
| 2010-05-13 |
Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010 |
None |
| 2010-05-13 |
Trubion Pharmaceuticals to present promising data from Phase 1 studies of SBI-087, SBI-087 |
None |
| 2010-05-13 |
Amarin reports cash balance of $44 million for first-quarter 2010 |
None |
| 2010-05-13 |
Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates |
None |
| 2010-05-13 |
CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer |
None |
| 2010-05-13 |
Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule |
None |
| 2010-05-12 |
Avexa halts HIV drug trials |
None |
| 2010-05-12 |
GTC Biotherapeutics reports lower total net loss of $7.7M for first-quarter 2010 |
None |
| 2010-05-12 |
NovaBay first-quarter net loss increases to $1.6 million |
None |
| 2010-05-12 |
Pro-Pharmaceuticals reports net loss applicable to common stock of $2.8M for first-quarter 2010 |
None |
| 2010-05-12 |
Capstone Therapeutics to continue to planned 12-month endpoints in AZX100 Phase 2a clinical trials |
None |
| 2010-05-12 |
FDA approves Aeterna Zentaris' AEZS-108 IND for bladder cancer |
None |
| 2010-05-12 |
Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD |
None |
| 2010-05-12 |
Updated data from Vical's Phase 2 trial of high-dose Allovectin-7 in metastatic melanoma patients |
None |
| 2010-05-12 |
Evotec first-quarter operating loss decreases 93% to € 1.5 m |
None |
| 2010-05-12 |
COTI announces favourable independent pre-IND gap analysis report for novel oncology drug candidate |
None |
| 2010-05-12 |
NiKem Research receives Italian authorization to perform toxicology studies of NCEs in rodents |
None |
| 2010-05-12 |
Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs |
None |
| 2010-05-12 |
Oncos Therapeutics completes € 4 million investment from HealthCap |
4 |
| 2010-05-12 |
Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients |
None |
| 2010-05-12 |
Gilead Sciences board authorizes $5 billion common stock repurchase program |
None |
| 2010-05-12 |
ChronTech Pharma receives six months' extension to buy back in ChronSeal ownership |
None |
| 2010-05-12 |
Pacira Pharmaceuticals receives $11.25M credit facility from GE Capital, Healthcare Financial Services |
None |
| 2010-05-12 |
Update on Nymox Pharmaceutical's Phase 3 program for NX-1207 |
None |
| 2010-05-12 |
Tianyin third-quarter revenue up 60% |
None |
| 2010-05-12 |
Phase IIb study of EVP-6124 initiated in patients with Alzheimer's disease |
None |
| 2010-05-12 |
Exelixis first-quarter revenues increase to $42.2 million |
None |
| 2010-05-12 |
Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients |
None |
| 2010-05-12 |
Preliminary data from Achillion Pharmaceuticals' Phase 1b clinical trial of ACH-1625 reported |
None |
| 2010-05-11 |
Pro-Pharmaceuticals completes $6 million private placement with 10X Fund |
None |
| 2010-05-11 |
EntreMed adds DF/HCC hospitals to Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer |
None |
| 2010-05-11 |
China Pharma first-quarter revenue up 16% to $15.1 million |
None |
| 2010-05-11 |
DUSA Pharmaceuticals first-quarter total product revenues up 22% |
None |
| 2010-05-11 |
MediciNova announces $15 million senior secured term loan with Oxford Finance |
None |
| 2010-05-11 |
Scancell signs worldwide licensing agreement with NIH for TRP-2 and gp100 melanoma antigens |
None |
| 2010-05-11 |
Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference |
None |
| 2010-05-11 |
Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010 |
None |
| 2010-05-11 |
Alexza Pharmaceuticals first-quarter net loss increases to $13.4 million |
None |
| 2010-05-11 |
CrystalGenomics completes European Phase I SAD study of CG400549 antibiotic candidate |
None |
| 2010-05-10 |
Generex Biotechnology enrolls over 400 subjects in global Phase III study of Generex Oral-lyn |
None |
| 2010-05-10 |
Enzon reports income from continuing operations of $20.8M for first-quarter 2010 |
None |
| 2010-05-10 |
QRxPharma reports successful outcome of Phase 1 trial for MoxDuo CR for chronic pain |
None |
| 2010-05-10 |
Harbor BioSciences reports encouraging results from Triolex Phase IIa trials |
None |
| 2010-05-10 |
Immunomedics third-quarter revenues increase to $10.7 million |
None |
| 2010-05-10 |
European patent strengthens Soligenix' topically active steroid intellectual property portfolio |
None |
| 2010-05-10 |
Achillion reports lower net loss of $5.6M for first-quarter 2010 |
None |
| 2010-05-10 |
MicroStockProfit.com features investment report on ARIAD Pharmaceuticals |
None |
| 2010-05-10 |
Lexicon Pharmaceuticals first-quarter revenues down 61% |
5 |
| 2010-05-10 |
Initiation of QVA149 Phase III clinical programme by Novartis triggers $7.5M milestone payment to Sosei |
None |
| 2010-05-07 |
Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting |
5 |
| 2010-05-07 |
Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010 |
None |
| 2010-05-07 |
Osiris Therapeutics reports net income of $2.4M for first-quarter 2010 |
None |
| 2010-05-07 |
Nile Therapeutics completes dose escalation in CD-NP Phase II study for acute decompensated heart failure |
None |
| 2010-05-07 |
Halozyme Therapeutics first-quarter net loss decreases to $11.8 million |
None |
| 2010-05-07 |
MicroStockProfit.com releases NexMed investment report |
None |
| 2010-05-07 |
Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010 |
None |
| 2010-05-07 |
Pfizer presents data on in vivo activity of PF-04523655 siRNA drug candidate at ARVO annual meeting |
None |
| 2010-05-07 |
Genzyme to initiate $2 billion stock buyback |
None |
| 2010-05-07 |
Nabi Biopharmaceuticals reports first-quarter net income of $5.5 million from continuing operations |
None |
| 2010-05-07 |
Oramed reports Phase 2b non-FDA clinical trial results of ORMD-0801 oral insulin capsule |
None |
| 2010-05-06 |
Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex |
None |
| 2010-05-06 |
Cytochroma reports positive results from Phase I trial for CTAP201 Injection in hemodialysis patients |
None |
| 2010-05-06 |
PurGenesis announces positive results from Phase I clinical trial of PUR0110 for ulcerative colitis |
5 |
| 2010-05-06 |
Momenta Pharmaceuticals first-quarter net loss decreases to $16.1 million |
None |
| 2010-05-06 |
Vical reports net loss of $8.5 million for first-quarter 2010 |
None |
| 2010-05-06 |
Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin |
None |
| 2010-05-06 |
Osiris Therapeutics resumes enrollment in Prochymal trial for treatment-resistant Crohn's disease |
None |
| 2010-05-06 |
CU-Boulder develops inhalable vaccine for measles prevention |
None |
| 2010-05-06 |
Pharmasset reports net loss of $16.1 million for fiscal second-quarter 2010 |
None |
| 2010-05-06 |
ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE |
None |
| 2010-05-06 |
Positive results from Phase 2 clinical study of LX1031 in IBS patients presented at DDW 2010 |
None |
| 2010-05-06 |
Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010 |
None |
| 2010-05-06 |
Positive results from Phase IIa clinical study of LIPO-102 |
None |
| 2010-05-06 |
Innate Therapeutics receives funding to conduct Phase 2A clinical trial for MIS416 |
None |
| 2010-05-06 |
Update on CEL-SCI's Phase III clinical trial of Multikine |
None |
| 2010-05-06 |
Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX |
None |
| 2010-05-05 |
Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients |
None |
| 2010-05-05 |
Rockwell Medical first-quarter sales up 17.1% |
None |
| 2010-05-05 |
Boehringer Ingelheim, Micromet enter collaboration for new BiTE antibody for multiple myeloma |
None |
| 2010-05-05 |
Aradigm receives FDA IND approval for inhaled liposomal ciprofloxacin |
None |
| 2010-05-05 |
AMRI first-quarter total revenue down 9% to $49.3 million |
None |
| 2010-05-05 |
Cadence Pharmaceuticals resubmits OFIRMEV NDA |
None |
| 2010-05-05 |
Merck acquires development, commercialization rights of ridaforolimus |
None |
| 2010-05-05 |
ARIAD restructures collaboration with Merck for ridaforolimus mTOR inhibitor |
None |
| 2010-05-05 |
Vical commences enrollment in Phase 1 trial of Vaxfectin DNA pandemic influenza vaccine |
None |
| 2010-05-05 |
Archivel Farma to start phase II clinical trials of RUTI vaccine for Latent Tuberculosis |
None |
| 2010-05-05 |
UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine |
None |
| 2010-05-05 |
Targeted antibiotics provide safe, long-lasting improvement for IBS patients, says study |
None |
| 2010-05-05 |
StemCells first-quarter total revenue up 307% |
None |
| 2010-05-05 |
Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010 |
None |
| 2010-05-05 |
ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial |
None |
| 2010-05-05 |
Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies |
None |
| 2010-05-05 |
S*BIO, Onyx Pharmaceuticals expand development, commercialization collaboration for JAK2 Inhibitors |
None |
| 2010-05-05 |
Results from STEALTH C-3 clinical trial of nitazoxanide presented at DDW 2010 |
None |
| 2010-05-05 |
Additional pivotal Phase 3 trial data for MoxDuo IR released |
None |
| 2010-05-05 |
Nymox Pharmaceutical announces new positive results from long term outcome study of NX-1207 for BPH |
None |
| 2010-05-05 |
Second fidaxomicin Phase 3 clinical study data in patients with CDI to be presented at DDW 2010 |
5 |
| 2010-05-05 |
BELLUS Health to discontinue NC-503 diabetes development program |
None |
| 2010-05-04 |
MAP Pharmaceuticals reports net loss $14.1 million for first-quarter 2010 |
None |
| 2010-05-04 |
Celldex reports net loss of $6.6 million for first-quarter 2010 |
None |
| 2010-05-04 |
Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010 |
None |
| 2010-05-04 |
Celsion reports $4.6 million net loss from operations for first-quarter 2010 |
None |
| 2010-05-04 |
Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI |
None |
| 2010-05-04 |
Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com |
None |
| 2010-05-04 |
MicroStockProfit.com releases investment report on Vical |
None |
| 2010-05-04 |
Ocera Therapeutics presents Phase 2 proof-of-concept study results of AST-120 in non-constipating IBS |
None |
| 2010-05-04 |
ADVENTRX Pharmaceuticals announces 6-month stability data for Exelbine |
None |
| 2010-05-04 |
Hologic commences enrollment in European trial of Gestiva for prevention of recurrent preterm birth |
None |
| 2010-05-04 |
Sucampo Pharmaceuticals presents Phase 2 cobiprostone clinical trial data at DDW 2010 |
None |
| 2010-05-04 |
Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010 |
None |
| 2010-05-04 |
Researchers present positive results of Phase II clinical trial of eliglustat tartrate |
None |
| 2010-05-04 |
Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010 |
None |
| 2010-05-03 |
NOXXON Pharma completes first-in-human clinical trial with Spiegelmer NOX-A12 |
None |
| 2010-05-03 |
NIAID researchers initiate trial of DAS181 in patients with asthma, bronchiectasis |
None |
| 2010-05-03 |
Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells |
None |
| 2010-05-03 |
Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting |
None |
| 2010-05-03 |
Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease |
None |
| 2010-05-03 |
ImmunoCellular Therapeutics seeks FDA orphan drug status for ICT-107 dendritic-cell based vaccine for GBM |
5 |
| 2010-05-03 |
Curis completes enrollment in Phase I clinical trial of CUDC-101 HDAC, EGFR and HER2 inhibitor |
None |
| 2010-05-03 |
BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development |
None |
| 2010-05-03 |
Penwest Pharmaceuticals reports net income of $3.9 million for first-quarter 2010 |
None |
| 2010-05-03 |
AVANIR Pharmaceuticals reports net loss of $6.4 million for second-quarter fiscal 2010 |
None |
| 2010-05-03 |
Omeros announces additional data from Phase 2 trial of OMS103HP for arthroscopic meniscectomy surgery |
None |
| 2010-05-03 |
Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments |
None |
| 2010-05-03 |
TGRD presents positive results from Phase 3 studies of azilsartan medoxomil for lowering SBP at 25th ASH |
None |
| 2010-05-03 |
SARcode presents positive results from Phase 2 study of SAR 1118 ophthalmic solution at Dry Eye Summit |
None |
| 2010-05-03 |
Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH |
None |
| 2010-05-03 |
Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study |
3 |
| 2010-05-03 |
Triple combination therapy with OM, AML, HCTZ more effective at lowering blood pressure |
None |
| 2010-05-03 |
Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials |
None |
| 2010-05-03 |
Results from VeriStrat biomarker analysis of Phase III trial presented at European Lung Cancer Conference |
None |
| 2010-05-03 |
FDA approves continuation of Phase IIb clinical trial for superficial bladder cancer |
None |